{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:57:45Z","timestamp":1778637465923,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012319","name":"National Center for Global Health and Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.antiviral.2020.104744","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T19:36:03Z","timestamp":1582054563000},"page":"104744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["7-Deaza-7-fluoro modification confers on 4\u2032-cyano-nucleosides potent activity against entecavir\/adefovir-resistant HBV variants and favorable safety"],"prefix":"10.1016","volume":"176","author":[{"given":"Sanae","family":"Hayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyo","family":"Higashi-Kuwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debananda","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Tomaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuko","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Venzon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichiro","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Isogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan G.","family":"Sarafianos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Mitsuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2020.104744_bib1","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1128\/JCM.37.9.2899-2903.1999","article-title":"Quantitation of hepatitis B virus genomic DNA by real-time detection PCR","volume":"37","author":"Abe","year":"1999","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2020.104744_bib2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.35772\/ghm.2019.01003","article-title":"A novel HIV-1 protease inhibitor, GRL-044, has potent activity against various HIV-1s with an extremely high genetic barrier to the emergence of HIV-1 drug resistance","volume":"1","author":"Aoki","year":"2019","journal-title":"Glob. Health Med."},{"key":"10.1016\/j.antiviral.2020.104744_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104744_bib4","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104744_bib5","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1002\/hep.22885","article-title":"Side effects of long-term oral antiviral therapy for hepatitis B","volume":"49","author":"Fontana","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104744_bib6","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jhep.2015.03.020","article-title":"Characterization of novel entecavir resistance mutations","volume":"63","author":"Hayashi","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104744_bib7","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02143-18","article-title":"CMCdG, a novel nucleoside analog with favorable safety features, exerts potent activity against wild-type and entecavir-resistant hepatitis B virus","volume":"63","author":"Higashi-Kuwata","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104744_bib8","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/hep.21627","article-title":"Management of hepatitis B: summary of a clinical research workshop","volume":"45","author":"Hoofnagle","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104744_bib9","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1128\/AAC.45.5.1539-1546.2001","article-title":"4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro","volume":"45","author":"Kodama","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104744_bib10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/nass\/42.1.127","article-title":"Synthesis of 4'-substituted nucleosides and their biological evaluation","author":"Kohgo","year":"1999","journal-title":"Nucleic Acids Symp. Ser."},{"key":"10.1016\/j.antiviral.2020.104744_bib11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1081\/NCN-120037508","article-title":"Design, efficient synthesis, and anti-HIV activity of 4'-C-cyano- and 4'-C-ethynyl-2'-deoxy purine nucleosides","volume":"23","author":"Kohgo","year":"2004","journal-title":"Nucleos Nucleot. Nucleic Acids"},{"key":"10.1016\/j.antiviral.2020.104744_bib12","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1021\/jm010418n","article-title":"Structure-activity relationships of 2'-fluoro-2',3'-unsaturated D-nucleosides as anti-HIV-1 agents","volume":"45","author":"Lee","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2020.104744_bib13","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jhep.2005.11.036","article-title":"Cellular and virological mechanisms of HBV drug resistance","volume":"44","author":"Locarnini","year":"2006","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104744_bib14","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1021\/jm00086a013","article-title":"Synthesis and anti-HIV activity of 4'-azido- and 4'-methoxynucleosides","volume":"35","author":"Maag","year":"1992","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2020.104744_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3851\/IMP2697","article-title":"Delayed emergence of HIV-1 variants resistant to 4'-ethynyl-2-fluoro-2'-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001","volume":"19","author":"Maeda","year":"2014","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2020.104744_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2014.04.005","article-title":"Nucleoside\/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance","volume":"8","author":"Men\u00e9ndez-Arias","year":"2014","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.antiviral.2020.104744_bib17","doi-asserted-by":"crossref","first-page":"35681","DOI":"10.1074\/jbc.M109.036616","article-title":"Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor","volume":"284","author":"Michailidis","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2020.104744_bib18","doi-asserted-by":"crossref","first-page":"24533","DOI":"10.1074\/jbc.M114.562694","article-title":"4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms","volume":"289","author":"Michailidis","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2020.104744_bib19","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1128\/AAC.00277-07","article-title":"Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine","volume":"51","author":"Nakata","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104744_bib20","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1073\/pnas.93.9.4398","article-title":"Viral dynamics in hepatitis B virus infection","volume":"93","author":"Nowak","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2020.104744_bib21","doi-asserted-by":"crossref","first-page":"7059","DOI":"10.1073\/pnas.86.18.7059","article-title":"Host-independent evolution and a genetic classification of the hepadnavirus family based on nucleotide sequences","volume":"86","author":"Orito","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2020.104744_bib22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1468-1293.2005.00318.x","article-title":"The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy","volume":"6","author":"Parsonage","year":"2005","journal-title":"HIV Med."},{"key":"10.1016\/j.antiviral.2020.104744_bib23","doi-asserted-by":"crossref","first-page":"9274","DOI":"10.1073\/pnas.1605223113","article-title":"Structural basis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA)","volume":"113","author":"Salie","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2020.104744_bib24","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/hep.27962","article-title":"4'-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus","volume":"62","author":"Takamatsu","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104744_bib25","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/hupa.2001.25586","article-title":"Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion","volume":"32","author":"Tanji","year":"2001","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.antiviral.2020.104744_bib26","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104744_bib27","series-title":"Global Hepatitis Report","author":"World Health Organization","year":"2017"},{"key":"10.1016\/j.antiviral.2020.104744_bib28","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.bbrc.2019.01.026","article-title":"Active-site deformation in the structure of HIV-1 RT with HBV-associated septuple amino acid substitutions rationalizes the differential susceptibility of HIV-1 and HBV against 4'-modified nucleoside RT inhibitors","volume":"509","author":"Yasutake","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219306059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219306059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:31:34Z","timestamp":1759062694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354219306059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":28,"alternative-id":["S0166354219306059"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104744","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"7-Deaza-7-fluoro modification confers on 4\u2032-cyano-nucleosides potent activity against entecavir\/adefovir-resistant HBV variants and favorable safety","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104744","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104744"}}